Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021)
Design Therapeutics recorded quarterly Total Non-Current Liabilities of $8.8 million in Q3 2021, up 157.8% quarter-over-quarter from $3.4 million in Q2 2021.
Design Therapeutics' Total Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $8.8 million for Q3 2021.
- In Q3 2021, Total Non-Current Liabilities changed N/A year-over-year to $8.8 million; the TTM figure through Sep 2021 stood at $8.8 million (changed N/A YoY), while the FY2020 annual figure was $2.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities came in at $8.8 million for Q3 2021 at Design Therapeutics, up from $3.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $8.8 million in Q3 2021 to a low of $2.3 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 8.78 Mn |
| Jun 30, 2021 | 3.41 Mn |
| Mar 31, 2021 | 3.71 Mn |
| Dec 31, 2020 | 2.33 Mn |